After achieving complete regression in several patients with different solid tumor types, Steven Rosenberg is eyeing the biggest prize imaginable—advancing the therapies he has championed for over four decades into the clinic as treatments for commonly occurring cancers.
![Conversation with The Cancer Letter](https://cdn.cancerletter.com/media/2020/11/18170519/qa-300x300.jpg)
![Conversation with The Cancer Letter](https://cdn.cancerletter.com/media/2020/11/18170519/qa-300x300.jpg)